YKL-05-099 is an experimental drug which acts as an inhibitor of the salt-inducible kinase (SIK) enzymes. It has antiinflammatory effects and is used for research into the potential applications of salt-inducible kinase inhibitors in treating several conditions including leukemia, osteoporosis and obesity.